Adhere/interpret the CINV guidelines |
49 |
48 |
3 |
47 |
50 |
2 |
Communicate with patients about CINV |
40 |
54 |
6 |
55 |
41 |
4 |
Differentiate between CINV therapies |
45 |
51 |
4 |
55 |
44 |
1 |
Integrate novel therapies for the prevention and treatment of CINV |
57 |
41 |
2 |
59 |
39 |
2 |
Keep up to date on emerging clinical data in CINV |
50 |
48 |
3 |
58 |
42 |
0 |
Options for managing radiation- and opioid-induced CINV |
37 |
57 |
6 |
48 |
48 |
4 |
Prevent/manage breakthrough nausea and vomiting |
55 |
41 |
4 |
62 |
36 |
2 |
Prevent/manage CINV in patients undergoing bone marrow transplant |
28 |
50 |
22 |
45 |
40 |
15 |
Prevent/manage CINV when administering multiday chemotherapy |
54 |
39 |
7 |
59 |
40 |
1 |
Prevent/manage nausea specifically |
40 |
56 |
4 |
54 |
44 |
2 |
Understand barriers to adherence with antiemetic guidelines |
34 |
56 |
10 |
50 |
46 |
5 |
Understand the consequences of untreated/uncontrolled CINV for the patient (and caregivers) |
38 |
53 |
9 |
49 |
48 |
3 |
Understand the pharmacoeconomic consequences of untreated/uncontrolled CINV |
37 |
50 |
13 |
49 |
46 |
5 |
Overcoming challenging CINV patient scenarios |
35 |
58 |
6 |
42 |
54 |
4 |
Personalizing CINV treatment |
44 |
53 |
3 |
51 |
48 |
2 |
Selecting the most effective therapies to prevent CINV |
54 |
45 |
1 |
53 |
47 |
1 |
Stratifying patients according to their risk for CINV |
39 |
57 |
3 |
42 |
53 |
5 |
Treating refractory CINV |
57 |
40 |
3 |
51 |
46 |
3 |
Understanding the mechanism of CINV therapies |
36 |
59 |
4 |
43 |
53 |
4 |
Understanding the patient-related factors that increase the risk of CINV |
41 |
57 |
3 |
47 |
53 |
4 |
Understanding the pathophysiology of CINV |
38 |
55 |
8 |
46 |
48 |
6 |
Understanding the side-effect profile of CINV therapies |
39 |
55 |
7 |
46 |
51 |
3 |
Utilizing standing orders for CINV |
25 |
59 |
15 |
41 |
53 |
6 |
Working as a multidisciplinary team to overcome CINV |
33 |
52 |
15 |
46 |
50 |
4 |